Advised Avomeen, a provider of analytical lab and pharma testing services, on its recapitilization with private equity firm High Street Capital.

Widely recognized as a leading expert in deformulation analysis, Avomeen has unique capabilities to separate, identify and quantitate ingredients in complex formulations.  These intricate techniques are used to provide solutions involving competitive product analysis, batch-to-batch product variation, product failure and product contamination as well as the development of generics for patent expiring pharmaceutical products.

Eric Williams the lead professional on the M&A team commented that the market is rewarding companies that can develop innovative and effective solutions to satisfy the increasing complexities of drug development, manufacturing and testing. Private equity is attracted to the sector due to its solid fundamentals, high fragmentation, strong growth dynamics and attractive exit options for businesses that achieve scale. The terms of the deal were not disclosed.

Avomeen Founder Shri Thanedar, Ph.D commented: “The expertise and capital that High Street brings to the table will enable us to expand and professionalize our business development efforts. We believe our deep scientific expertise and consultative approach will be well received as we secure new clients and enter new markets.”